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Abstract Anderson-Fabry disease (AFD) is a multiorgan
X-linked lysosomal storage disease that particularly affects
the heart, kidneys, and cerebrovascular system. Current
treatment is enzyme replacement therapy (ERT) with
agalsidase beta (Fabrazyme®, Genzyme Corporation, Cam-
bridge, MA, USA) or agalsidase alfa (Replagal®, Shire
Human Genetic Therapies AB, Lund, Sweden). It was
recommended that patients switch to agalsidase alfa due to
a manufacturing shortage of agalsidase beta beginning in
June 2009. This study assessed the effect of switching to
agalsidase alfa on clinical outcomes in patients with AFD
previously treated with agalsidase beta. Ten patients (seven
male, three female) with genetically confirmed AFD and at
least 48 months’ continuous data collected during treatment
with agalsidase beta 1 mg/kg every other week were
switched to agalsidase alfa 0.2 mg/kg every other week
for at least 20 months, with prospective clinical evaluations
every 6 months. Pre-switch data was collected retrospec-
tively from patient charts. Cardiac functional parameters
were assessed using magnetic resonance imaging. Results
showed that renal function was normal (estimated glomerular
filtration rate 90 mL/min/1.73 m2) in 8 of 10 patients
prior to agalsidase alfa and generally remained stable after
the switch. Cardiac mass decreased significantly (p < 0.05
vs pre-ERT) after agalsidase beta and remained unchanged
after switching to agalsidase alfa. Symptoms of pain and
health status scores did not deteriorate during agalsidase
alfa therapy. Adverse events were mostly mild and infusion
related. In conclusion, switching to agalsidase alfa was
relatively well tolerated and associated with stable clinical
status and preserved renal and cardiac function.
Introduction
Anderson-Fabry disease is an X-linked lysosomal storage
disorder caused by a deficiency of the hydrolytic enzyme
a-galactosidase A (a-Gal A). Consequently, globotriaosyl-
ceramide (Gb3) accumulates in cells and tissues of the body
resulting in a multisystem pathology (Brady et al. 1967;
Desnick et al. 2001), affecting the skin, nervous and
cerebrovascular systems, kidneys, and heart, and is asso-
ciated with a reduced life expectancy (Zarate and Hopkin
2008). Renal involvement is progressive, eventually leading
to end-stage renal disease (ESRD) by the fourth and fifth
decades of life if untreated; prior to the advent of dialysis
and renal transplantation, ESRD was the leading cause of
death (Branton et al. 2002). Cardiac manifestations include
left ventricular (LV) hypertrophy, valvular disease, conduc-
tion abnormalities leading to arrhythmias, congestive heart
failure, and coronary artery disease (Weidemann et al.
2005; Linhart and Elliott 2007; Kampmann et al. 2008;
Linhart 2008; Morrissey et al. 2011).
Two recombinant enzyme formulations for enzyme
replacement therapy (ERT) of Anderson-Fabry disease
have been commercially available in Europe for almost
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10 years: agalsidase alfa (Replagal®, Shire Human Genetic
Therapies AB, Danderyd, Sweden) and agalsidase beta
(Fabrazyme®, Genzyme Corporation, Cambridge, MA,
USA) (Smid et al. 2011). Numerous clinical trials,
observational studies, and registry data have provided some
evidence for the safety and efficacy of ERT in improving
disease symptoms, cardiac mass, renal function, and quality
of life (Eng et al. 2001; Schiffmann et al. 2001; Weidemann
et al. 2003; Wilcox et al. 2004; Banikazemi et al. 2007;
Hughes et al. 2008; Koskenvuo et al. 2008; Imbriaco et al.
2009; Mehta et al. 2009; Feriozzi et al. 2012). To date,
there have been limited comparisons of the two agents,
from which no firm conclusion can be drawn regarding
their relative efficacy and safety (Lidove et al. 2010).
As of June 2009, viral contamination in the agalsidase
beta production facility resulted in a worldwide supply
shortage of agalsidase beta (European Medicines Agency
2009). It was initially recommended by the European
Medicines Agency (EMA) that priority patients continue
on a reduced dosage of agalsidase beta (European Medi-
cines Agency 2009) but this appeared to be associated with
an increase in the adverse event rate, prompting the EMA to
revise their recommendation about a year later to treatment
with either the full dose of agalsidase beta (1 mg/kg every
2 weeks) or agalsidase alfa (0.2 mg/kg every 2 weeks)
(European Medicines Agency 2010a, b). An expert consen-
sus guidelines published in 2011 recommended a similar
approach (Linthorst et al. 2011). Data on the effect of
switching between the two therapies are limited to one
observational study in 11 Japanese patients (Tsuboi and
Yamamoto 2012) and a subgroup of 20 patients in a
retrospective cohort Dutch study (Smid et al. 2011). Both
reported clinical outcomes, including effects on cardiac
abnormalities, but neither assessed cardiac effects via
cardiac magnetic resonance imaging (cMRI).
We aimed to assess the effect of switching from
agalsidase beta to agalsidase alfa on renal function, cardiac
functional parameters (assessed via cMRI), health status,
pain, and adverse events in patients with Anderson-Fabry
disease by comparing retrospective data during treatment
with agalsidase beta with prospective data during 20
months’ treatment with agalsidase alfa.
Materials and Methods
Study Design
This was a single-center observational study conducted at
the University Hospital Federico II, Italy, of patients with
Anderson-Fabry disease who switched from treatment with
agalsidase beta to agalsidase alfa. Data for the period during
which patients received agalsidase beta was gathered
retrospectively. Data collected at the time patients switched
to agalsidase alfa and during agalsidase alfa treatment was
gathered prospectively.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the institu-
tional ethics committee. All patients switched to agalsidase
alfa and included in the final study population provided
written informed consent.
Patients
Patients eligible for study inclusion were those with a
genetically confirmed diagnosis of Anderson-Fabry disease,
at least 48 months of continuous data during treatment with
agalsidase beta 1 mg/kg (i.e., prior to switching), those
switched to agalsidase alfa after the start of the agalsidase
beta shortage, and patients who provided written informed
consent. Patients excluded from the study included those
who had received agalsidase beta at other than the
recommended dose for >12 months prior to the study or
who had used any investigational drug within 30 days prior
to study entry.
Treatments
Patients receiving agalsidase beta at a dosage of 1 mg/kg
every other week for a minimum of 48 months were
switched without any crossover period or interval to
agalsidase alfa 0.2 mg/kg every other week, given accord-
ing to the manufacturer’s prescribing information. Patients
received agalsidase alfa for a minimum of 20 months.
Pretreatment with an antihistamine and/or ibuprofen was
allowed to minimize infusion-associated reactions (IAR).
Concomitant treatments such as antihypertensive agents
were allowed.
Data Collection and Study End Points
Study endpoints included renal function, selected cardiac
parameters, pain symptoms, and patient health status. The
following clinical evaluations were performed at baseline,
after 48 months of ERT with agalsidase beta, and again
after 20 months ERT with agalsidase alfa: (1) physical
examination, routine blood chemistries, hematology, and
urinalysis; (2) serum creatinine levels and the mean
estimated glomerular filtration rate (GFR), calculated by
the Modification of Diet in Renal Disease (MDRD) study
equation (Levey et al. 1999) on the basis of patients’ age,
race, sex, and serum-creatinine values; (3) proteinuria
(estimated via the urine protein to creatinine ratio);
(4) 12-lead electrocardiography (ECG); (5) cMRI was used
to determine LV mass, LV wall thickness, and LV ejection
fraction (see separate section for cMRI Techniques and
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Analysis); (6) health status, evaluated with the Short Form-
36 (SF-36) Health Status Survey (Ware 1997); and (7) pain
score, evaluated with the short form McGill pain question-
naire (Melzack 1987). Use of concomitant medications,
including pain medication and antihypertensive agents was
recorded. In addition, a-Gal A enzyme activity was
assessed at diagnosis (Desnick et al. 1973).
Data collected during treatment with agalsidase beta was
obtained retrospectively from patient medical charts for the
48 months prior to the treatment switch. Retrospective data
included all endpoints as described above for the prospec-
tive part of the study and, in addition, the results of a
physical examination and cMRI prior to initiation of
agalsidase beta.
cMRI Technique and Analysis
cMRI assessments were performed pre-ERT, after 48
months’ agalsidase beta (before switching), and after 20
months’ agalsidase alfa, using a 1.5 Tesla MRI system
(Gyroscan Intera, Philips Medical System, Best, the
Netherlands) equipped with high-performance gradients
(maximum gradient amplitude 30 mT/m, maximum slew
rate 150 mT/m/ms). Images were acquired with a 5-element
cardiac phased-array coil using a vector cardiographic
method for ECG gating and respiratory gating. After
performing a survey scan, LV long axis and 4-chamber
horizontal long axis images were acquired using a breath-
holding 2D balanced turbo field echo multiphase-multislice
sequence (TR/effective TE, 2.8/1.4; matrix, 160X256; slice
thickness, 10-mm; flip angle, 50); subsequently, biven-
tricular short-axis images were obtained using 9–10 slices
covering the left ventricle from the apex to the base for
evaluation of LV mass. The total acquisition time ranged
between 25 and 30 min for each assessment.
Post-processing was performed on a dedicated worksta-
tion (Viewforum, Philips Medical System, Best, the Nether-
lands). LV wall thickness was measured at the level of the
mid-septum. Analysis of LV mass was performed choosing
the slice with the greatest cardiac diameter of the
2D-balanced turbo field echo multiphase-multislice acquisi-
tion in the biventricular short axis; subsequently, the
endocardial and the epicardial borders were manually traced,
carefully including the papillary muscles, on each end-
diastolic and end-systolic frame for each of the 9–10 slices.
The evaluation of late gadolinium enhancement (LGE),
looking for areas of myocardial fibrosis, although not a goal
of this study, was assessed and only in two cases were these
additional MR sequences observed. In particular, a com-
mercially available gadolinium-based contrast agent, gado-
diamide (gadopentetate dimeglumine – Magnevist,
Schering AG, Berlin, Germany; 0.15 mmol/kg), was
injected intravenously at a dose of 0.1 mmol/kg of body
weight, and 10–15 min after the injection, a segmented
inversion-recovery fast-gradient echo sequence was
acquired. LGE images were acquired in multiple short-axis
views identical to those obtained for cine cardiac MRI.
Finally, a visual estimation of LGE extent in LV horizontal,
vertical long-axis, and short axis views was subsequently
performed.
Safety
The safety of agalsidase alfa was assessed by recording all
adverse events (AEs), which were assessed for their
severity and relationship to the study drug.
Statistical Analysis
Data are mean  standard deviation (SD) unless specified
otherwise. Differences in LV parameters between pre-ERT
and agalsidase beta treatment, and between agalsidase beta
and agalsidase alfa treatment, were analyzed using a
Student t-test for paired observations. Value of p < 0.05
was considered statistically significant.
Results
Patients
Of the 14 patients with Anderson-Fabry disease receiving
agalsidase beta at our institution, 10 agreed to switch to
agalsidase alfa, 2 patients opted for the reduced agalsidase
beta dosage (0.3 mg/kg every other week) and 1 discon-
tinued ERT. Ten patients (mean  SD age 44  5 years)
with genetically confirmed Anderson-Fabry disease met
study inclusion criteria and were enrolled (seven male,
three female) into the prospective part of the study. A
causal mutation/deletion was identified in all patients
included in this study.
Renal Function
Renal function, assessed by serum creatinine levels and
eGFR, remained stable in both male and female patients 24
months after switching treatment (Table 1). Individual
eGFR values confirmed this finding, with no patient
demonstrating clinically significant changes in eGFR after
the ERT switch (Table 2). At entry to the evaluation, eGFR
was normal (eGFR 90 ml/min/1.73 m2) in 8 of the 10
patients, and remained normal during the 20-month follow-
up. Two patients had elevated serum creatinine levels at the
start of the switch but these levels did not worsen with
agalsidase alfa treatment (data not shown). The median
urinary protein to creatinine ratio was 0.96 (in mg protein/
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mMol creatinine) pre-ERT, 0.36 after 48 months’ agalsidase
beta therapy (before switching to agalsidase alfa), and 0.38
after 20 months’ agalsidase alfa therapy, indicating a
stabilization in urine protein excretion. Individual patient
data showed that those patients who experienced an
increase in urine protein excretion had relatively high
proteinuria at baseline (data not shown).
Cardiac Functional Parameters
Cardiac function (assessed by LV ejection fragment
[LVEF]) remained unchanged after a switch from agalsi-
dase beta to agalsidase alfa (Table 1); pre-ERT LVEF
values did not change significantly after agalsidase beta or
agalsidase alfa therapy. LV mass index and LV wall
thickness decreased significantly (p < 0.05) from pre-ERT
values after 48 months’ treatment with agalsidase beta as
shown in Table 1. These reductions were maintained when
patients were switched to agalsidase alfa, as there were no
significant differences in these parameters after 20 months’
treatment with agalsidase alfa compared with values after
48 months’ agalsidase beta treatment. Individual changes in
left ventricular functional parameters measured at baseline
after 48 months of therapy with agalsidase beta and after
20  3 months of agalsidase alfa therapy are shown in
Table 3.
No significant correlation was observed between the age
of the patients and the variation in LV functional parameters
(p > 0.05) with agalsidase beta or with agalsidase alfa
treatment.
Five male patients showed signs of LV hypertrophy
(LVH) before starting ERT with agalsidase beta. LVH
improved after 48 months’ therapy with agalsidase beta,
and this remained at a stable level after 20 months’
agalsidase alfa ERT. Figure 1 shows no changes in LV
wall thickness and LV mass, between study 2 and 3 in a
50-year-old male patient with Anderson-Fabry Disease.
Quality of Life
For most components of the SF-36 questionnaire, there
were no differences in mean scores after agalsidase alfa
treatment compared with the pre-switch period (data not
shown). No variations from pre-treatment through month
20 were seen for the components of Physical Functioning,
Role Emotional, Body Pain, and Standardized Physical
Table 1 Selected study endpoints at pre-ERT, after 48 months’ treatment with agalsidase beta and 20 months’ agalsidase alfa. Data are
mean  SD values unless stated otherwise
Pre-ERT After 48 months’ agalsidase beta After 20 months’ agalsidase alfa
Renal function
eGFR (L/min/1.73 m2) 92.4  13.1 91.3  14.9 90.3  17.5
Median (range) eGFR (L/min/1.73 m2) 98 (67–100) 97.5 (60–100) 96 (60–100)
Proteinuria
Urinary protein to creatinine ratio 0.96  0.29 0.36  0.14 0.38  0.07
Cardiac parameters
LV mass (g/m2) 106  32 73  24a,b 70  24
LV wall thickness (mm) 16  4 13  4a,b 13  3
LVEFc (%) 63  4 65  6 64  6
eGFR estimated glomerular filtration rate; LV left ventricular; LVEFc LV ejection fraction, corrected; SD standard deviation
a p < 0.05 vs baseline
b p > 0.05 vs agalsidase alfa
c p > 0.05 baseline vs agalsidase beta vs agalsidase alfa
Table 2 Individual patient data for estimated glomerular filtration rate
(GFR; L/min/1.73 m2) at baseline and after 48 months’ treatment with







1 100 100 98
2 68 68 65
3 67 60 60
4 100 100 100
5 98 98 96
6 98 96 95
7 97 97 97
8 98 96 96
9 98 98 96
10 100 100 100
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Component Scale; only small improvements were observed
for the other components, although none reached statistical
significance (data not included).
Pain Symptoms
Mean pain scores improved during agalsidase beta ERT and
then remained stable (i.e., no worsening) during treatment
with agalsidase alfa (data not inclued). Of the 10 patients,
8 had no pain at switching and remained pain free during
treatment with agalsidase alfa; 2 patients were experiencing
pain at the time of switching, but then improved slightly
during the agalsidase alfa ERT period.
Tolerability
There were no reports of treatment-related atrial fibrillation,
ventricular premature beats, tachyarrhythmia, cardiac failure,
or other cardiac adverse events within 24 h of administration
of ERT for every infusion given during the 20 months’
agalsidase alfa ERT period. Six patients experienced at least
one AE during treatment with agalsidase alfa. Most AEs were
mild in nature and unrelated to treatment. The most common
treatment-related AEs were IAR, consisting of rigors,
temperature change sensations, fever, nausea, headache,
vomiting, flushing, rhinitis, pruritus, and somnolence. Most
IARs were assessed as mild, and the total number of patients
who experienced an IAR markedly decreased over time
(data not shown). There were no abnormal laboratory test
values. No major AE were observed during treatment with
agalsidase beta.
Discussion
Renal and cardiac function, pain symptoms and health status
were largely unchanged when 10 patients with Anderson-
Fabry disease switched from ERT with agalsidase beta to
Table 3 Left ventricular functional parameters measured at baseline (1), after 48 months of therapy with agalsidase beta (2) and after 20  3
months of therapy with agalsidase alfa (3)
Pts (n ¼ 10) Age/Gender LVMI (g/m2) LVMI (g/m2) LVMI (g/m2) LVWT (mm) LVWT (mm) LVWT (mm)
Time point 1 2 3 1 2 3
1 56/M 167 113 92 21 15 15
2 43/M 82 70 64 15 15 13
3 44/M 77 55 53 15 10 12
4 43/F 147 111 116 22 22 20
5 38/F 93 62 64 15 11 13
6 40/M 66 71 54 13 9 10
7 41/M 98 75 64 12 10 10
8 50/M 121 50 52 15 14 13
9 40/F 85 41 42 14 12 11
10 48/M 124 86 96 14 12 15
LVMI left ventricular mass index, LVWT left ventricular wall thickness
Fig. 1 Left ventricular short axis view in a 50-year-old male with Anderson-Fabry disease showing no changes in LV mass index and LV wall
thickness between 48 months’ ERT with agalsidase beta (50 g/m2, 14 mm) and after 20 months’ ERT with agalsidase alfa (52 g/m2, 14 mm)
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agalsidase alfa for 20 months, suggesting patients main-
tained disease stability. The switch in treatment was
generally well tolerated.
These results largely confirm those reported by Tsuboi
et al. in a similarly designed study in 11 Japanese patients
with Anderson-Fabry disease (Tsuboi and Yamamoto
2012). In their study, eGFR also remained stable when
patients switched to agalsidase alfa. Unlike the current
study, their echocardiographic findings suggested improve-
ments in LV mass index and wall thickness after 12 months
agalsidase alfa treatment compared with agalsidase beta
treatment (Tsuboi and Yamamoto 2012). They reported a
similar lack of increase in pain symptoms or deterioration
in quality of life with the switch in treatment to the current
study. In addition, the results of the current study also
support those of a retrospective cohort study of the effects
of the agalsidase beta shortage on patients with Anderson-
Fabry disease, where 20 patients switched to agalsidase
alfa, 18 of whom did so only after taking reduced-dose
agalsidase beta, and 15 stayed on agalsidase beta but at a
reduced dose (Smid et al. 2011). There was no increase in
the clinical event incidence rate during the shortage
(clinical events included neurological, renal, and cardiac
events).
Most, but not all (Koskenvuo et al. 2008; Kovacevic-
Preradovic et al. 2008), prior studies that investigated the
effects of ERT (agalsidase beta or agalsidase alfa) on
cardiac functional parameters reported improvements in
cardiac parameters after initiation of ERT (Weidemann
et al. 2003; Beck et al. 2004; Hughes et al. 2008; Vedder
et al. 2008; Imbriaco et al. 2009). Results of the current
study were in agreement with the majority of these studies,
i.e., LV mass and wall thickness decreased significantly
from pre-ERT values after initiation of ERT, which in this
case was with agalsidase beta (retrospective data; see
Table 1). In particular, Eng et al. (2001) demonstrated in a
placebo-controlled, double-blind study that agalsidase beta
(1 mg/kg) resulted in a histological clearance of Gb3
deposits in myocardial endothelial cells; this effect was
sustained over 54 months of therapy (Germain et al. 2007).
Furthermore, Weidemann et al. suggested that clearance of
Gb3 by agalsidase beta leads to a regression of LV
hypertrophy, which was documented by echocardiography
and confirmed by MRI (Weidemann et al. 2003). Sustained
treatment with adequate doses of enzyme is of particular
importance as an in vitro study has shown that a relatively
limited percentage of administered enzyme reaches the
cardiac compartment (Ioannou et al. 2001). The current
study did not measure plasma or myocardial Gb3 levels;
thus, whether myocardial Gb3 deposits were reduced after
sustained ERT for 48 months with agalsidase beta and then
20 months with agalsidase alfa in this study is not known.
The Tsuboi et al. switch study did not measure myocardial
Gb3 levels either, but their patients experienced an increase
in plasma Gb3 levels after the switch from agalsidase beta
to alfa treatment (Tsuboi and Yamamoto 2012). Neverthe-
less, patients still experienced reductions in LV mass after
the switch. The authors queried the relevance of Gb3 levels
as biomarkers of Fabry disease.
It has been recommended that patients receiving ERT are
also prescribed angiotensin converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB) to reduce
the risk of proteinuria (Ortiz et al. 2008; Oqvist et al. 2009;
Mehta et al. 2010; Warnock et al. 2010). In our study, seven
patients were receiving ACEI and/or ARB therapy. Most of
these patients started ACEI/ARB therapy at the outset of
ERT. Some patients received both ACEI and ARB agents;
the dosages of ACEI/ARB therapy and other agents that
could affect kidney function and proteinuria were adjusted
empirically, depending on individual baseline proteinuria
levels, response to antiproteinuric therapy, and tolerance of
the antihypertensive effects. Antiproteinuric therapy was
continued throughout the study period. We ascribed the
significant drop in urinary protein observed during the ERT
period to concomitant use of ACEI/ARB therapy and ERT.
The present study has some potential limitations that
should be considered, including the relatively small number
of evaluated patients and the relatively short time of
switching therapy. Further study in larger patient popula-
tions is warranted, and according to ClinicalTrials.gov, a
switching study with a planned enrolment of 200 patients is
under way in the USA (NCT01268241) (ClinicalTrials.gov.
2012). It is the nature of many studies of rare diseases that
they are underpowered due to the difficulty in enrolling
sufficient eligible patients within a reasonable time frame.
However, underpowered studies for rare diseases are
justified and ethical in that they allow clinical data to be
amassed over time and these data can then be consolidated
in meta-analyses, thereby increasing the power and strength
of the findings and adding to the clinical evidence base.
Development of neutralizing IgG or IgE antibodies to
agalsidase alfa or agalsidase beta were not determined in
this study, although switching treatments is not expected to
prevent IgG antibody formation or related adverse effects
because of complete cross reactivity (Linthorst et al. 2004).
Nevertheless, our study is the first MRI study reporting
positive long-term effects of switching therapy ERT on
cardiac performance in patients with Anderson-Fabry
disease.
Conclusions
The results of the present study demonstrate that switching
therapy from agalsidase beta to agalsidase alfa, the two
products currently available for treatment of patients with
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Anderson-Fabry disease, did not result in significant
changes in renal function or cardiac functional parameters,
pain symptoms or health status, and was generally well
tolerated. Patients were able to maintain a clinically stable
disease state after the switch to long-term agalsidase alfa
treatment.
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